Michael Weintraub, MD
@mweintraubmd.bsky.social
Endocrinologist & Clin. Asst. Prof. @NYULangone | @WeillCornell and @Sloan_Kettering endocrine fellow alum. Opinions=own
#MedSky #EndoSky
#MedSky #EndoSky
We should be screening everyone with hypertension for primary aldosteronism, according to the recently released Endocrine Society guidelines.
Follow this diagnostic algorithm
Full guidelines: academic.oup.com/jcem/article...
Follow this diagnostic algorithm
Full guidelines: academic.oup.com/jcem/article...
September 24, 2025 at 8:02 AM
We should be screening everyone with hypertension for primary aldosteronism, according to the recently released Endocrine Society guidelines.
Follow this diagnostic algorithm
Full guidelines: academic.oup.com/jcem/article...
Follow this diagnostic algorithm
Full guidelines: academic.oup.com/jcem/article...
How to individualize obesity medication treatment depending on obesity-related conditions.
Great summary by the newly released update to the AACE Evaluation and Treatment of Adults with Obesity 2025 Consensus Statement
www.endocrinepractice.org/article/S153...
Great summary by the newly released update to the AACE Evaluation and Treatment of Adults with Obesity 2025 Consensus Statement
www.endocrinepractice.org/article/S153...
September 19, 2025 at 6:15 PM
How to individualize obesity medication treatment depending on obesity-related conditions.
Great summary by the newly released update to the AACE Evaluation and Treatment of Adults with Obesity 2025 Consensus Statement
www.endocrinepractice.org/article/S153...
Great summary by the newly released update to the AACE Evaluation and Treatment of Adults with Obesity 2025 Consensus Statement
www.endocrinepractice.org/article/S153...
Developing clinical practice guidelines is quite a process.
The GRADE format methodology translates evidence to medication decision-making recommendations after performing systemic review of the available evidence.
www.bmj.com/content/389/...
The GRADE format methodology translates evidence to medication decision-making recommendations after performing systemic review of the available evidence.
www.bmj.com/content/389/...
September 8, 2025 at 3:14 PM
Developing clinical practice guidelines is quite a process.
The GRADE format methodology translates evidence to medication decision-making recommendations after performing systemic review of the available evidence.
www.bmj.com/content/389/...
The GRADE format methodology translates evidence to medication decision-making recommendations after performing systemic review of the available evidence.
www.bmj.com/content/389/...
A higher BMI is correlated with increased risk of overall mortality. It follows the same overall curve as higher cholesterol and blood pressure, as illustrated in these graphs 📈
Controlling any and all of these risk factors lowers our overall risk of death.
pubmed.ncbi.nlm.nih.gov/28489290/
Controlling any and all of these risk factors lowers our overall risk of death.
pubmed.ncbi.nlm.nih.gov/28489290/
August 25, 2025 at 12:39 PM
A higher BMI is correlated with increased risk of overall mortality. It follows the same overall curve as higher cholesterol and blood pressure, as illustrated in these graphs 📈
Controlling any and all of these risk factors lowers our overall risk of death.
pubmed.ncbi.nlm.nih.gov/28489290/
Controlling any and all of these risk factors lowers our overall risk of death.
pubmed.ncbi.nlm.nih.gov/28489290/
Obesity rates have skyrocketed starting in the 1970s now reaching 40% in the United States.
"It seems highly unlikely that the obesity epidemic can be explained by a widespread drop in willpower happening in the late 1970s."
www.cell.com/cell/fulltex...
"It seems highly unlikely that the obesity epidemic can be explained by a widespread drop in willpower happening in the late 1970s."
www.cell.com/cell/fulltex...
August 21, 2025 at 11:11 PM
Obesity rates have skyrocketed starting in the 1970s now reaching 40% in the United States.
"It seems highly unlikely that the obesity epidemic can be explained by a widespread drop in willpower happening in the late 1970s."
www.cell.com/cell/fulltex...
"It seems highly unlikely that the obesity epidemic can be explained by a widespread drop in willpower happening in the late 1970s."
www.cell.com/cell/fulltex...
A collection of all my favorite podcasts to stay up to date in Diabetes Care
Check out this Marvel-style crossover episode hosted at ADA.
overcast.fm/+AABFhuN39pM
Check out this Marvel-style crossover episode hosted at ADA.
overcast.fm/+AABFhuN39pM
Special Edition - ADA Scientific Sessions 2025 — Diabetes Core Update
In this special edition of Diabetes Core Update we present a special podcast recorded live at the ADA Scientific Sessions by the editors of Diabetes Core Update, Diabetes Care On Air, Diabetes Bio,…
overcast.fm
August 18, 2025 at 11:40 AM
A collection of all my favorite podcasts to stay up to date in Diabetes Care
Check out this Marvel-style crossover episode hosted at ADA.
overcast.fm/+AABFhuN39pM
Check out this Marvel-style crossover episode hosted at ADA.
overcast.fm/+AABFhuN39pM
Rates of obesity of BMI 30-40 have had a mild increase over the last 20 years.
Rates of severe obesity BMI > 60 has dramatically risen- this graph is impressive.
Slide by Dr. Satya Dash at #ENDO2025
Rates of severe obesity BMI > 60 has dramatically risen- this graph is impressive.
Slide by Dr. Satya Dash at #ENDO2025
July 13, 2025 at 11:55 PM
Rates of obesity of BMI 30-40 have had a mild increase over the last 20 years.
Rates of severe obesity BMI > 60 has dramatically risen- this graph is impressive.
Slide by Dr. Satya Dash at #ENDO2025
Rates of severe obesity BMI > 60 has dramatically risen- this graph is impressive.
Slide by Dr. Satya Dash at #ENDO2025
Pheochromocytoma survival curves are dismal, particularly in those with metastatic disease. We need better treatments for these patients.
Excellent lecture by Dr. Camilo Jimenez at #ENDO2025
Excellent lecture by Dr. Camilo Jimenez at #ENDO2025
July 13, 2025 at 4:48 PM
Pheochromocytoma survival curves are dismal, particularly in those with metastatic disease. We need better treatments for these patients.
Excellent lecture by Dr. Camilo Jimenez at #ENDO2025
Excellent lecture by Dr. Camilo Jimenez at #ENDO2025
Studies showing benefits of GLP1 agonists in type 1 diabetes are accumulating.
Modest A1c reduction but impressive reductions in total daily insulin dose and weight reduction.
#ENDO2025
Modest A1c reduction but impressive reductions in total daily insulin dose and weight reduction.
#ENDO2025
July 12, 2025 at 7:07 PM
Studies showing benefits of GLP1 agonists in type 1 diabetes are accumulating.
Modest A1c reduction but impressive reductions in total daily insulin dose and weight reduction.
#ENDO2025
Modest A1c reduction but impressive reductions in total daily insulin dose and weight reduction.
#ENDO2025
Retatrutide may be the most hotly anticipated GLP-1 based medication in development 🔥💊, but others are not far behind 🏃.
A triple agonist, UBT251, is under development in China 🇨🇳 and also mimics GLP-1, GIP, and glucagon 🧬⚗️.
A triple agonist, UBT251, is under development in China 🇨🇳 and also mimics GLP-1, GIP, and glucagon 🧬⚗️.
July 11, 2025 at 1:45 PM
Retatrutide may be the most hotly anticipated GLP-1 based medication in development 🔥💊, but others are not far behind 🏃.
A triple agonist, UBT251, is under development in China 🇨🇳 and also mimics GLP-1, GIP, and glucagon 🧬⚗️.
A triple agonist, UBT251, is under development in China 🇨🇳 and also mimics GLP-1, GIP, and glucagon 🧬⚗️.
“Food noise” is the “incessant mental chatter” or “constant rumination” about food.
It is increasingly recognized as a phenomenon particularly with its profound elimination with GLP1 treatment.
New Nature review: www.nature.com/articles/s41...
Great overview: conscienhealth.org/2025/07/lift...
It is increasingly recognized as a phenomenon particularly with its profound elimination with GLP1 treatment.
New Nature review: www.nature.com/articles/s41...
Great overview: conscienhealth.org/2025/07/lift...
July 9, 2025 at 12:16 PM
“Food noise” is the “incessant mental chatter” or “constant rumination” about food.
It is increasingly recognized as a phenomenon particularly with its profound elimination with GLP1 treatment.
New Nature review: www.nature.com/articles/s41...
Great overview: conscienhealth.org/2025/07/lift...
It is increasingly recognized as a phenomenon particularly with its profound elimination with GLP1 treatment.
New Nature review: www.nature.com/articles/s41...
Great overview: conscienhealth.org/2025/07/lift...
“If you treat someone’s blood pressure or cholesterol you don’t get improvements in quality of life. You treat their weight you get all the benefits."
"That is the power of treating obesity.”
Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at #ADASciSessions #ADA2025
"That is the power of treating obesity.”
Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at #ADASciSessions #ADA2025
July 5, 2025 at 9:57 AM
“If you treat someone’s blood pressure or cholesterol you don’t get improvements in quality of life. You treat their weight you get all the benefits."
"That is the power of treating obesity.”
Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at #ADASciSessions #ADA2025
"That is the power of treating obesity.”
Inspiring talk by Dr. Lou Aronne on the clinical implications of CagriSema at #ADASciSessions #ADA2025
The long awaited triple agonist retatrutide phase 3 data is still pending ⏳🧪.
However, a body composition subanalysis of the phase 2 data is newly published 📄 showing lean mass loss of 38% of total weight loss 💪📉.
However, a body composition subanalysis of the phase 2 data is newly published 📄 showing lean mass loss of 38% of total weight loss 💪📉.
July 1, 2025 at 3:32 PM
The long awaited triple agonist retatrutide phase 3 data is still pending ⏳🧪.
However, a body composition subanalysis of the phase 2 data is newly published 📄 showing lean mass loss of 38% of total weight loss 💪📉.
However, a body composition subanalysis of the phase 2 data is newly published 📄 showing lean mass loss of 38% of total weight loss 💪📉.
The etiology of obesity is most often multifactorial- a combination of environmental factors and genetic predisposition among thousands of genes.
However, a portion of cases are due to a single genetic cause, such as in the leptin-melanocortin pathway.
academic.oup.com/edrv/article...
However, a portion of cases are due to a single genetic cause, such as in the leptin-melanocortin pathway.
academic.oup.com/edrv/article...
June 30, 2025 at 4:51 PM
The etiology of obesity is most often multifactorial- a combination of environmental factors and genetic predisposition among thousands of genes.
However, a portion of cases are due to a single genetic cause, such as in the leptin-melanocortin pathway.
academic.oup.com/edrv/article...
However, a portion of cases are due to a single genetic cause, such as in the leptin-melanocortin pathway.
academic.oup.com/edrv/article...
What is the impact of tirzepatide on body composition? 🤔
There was an absolute loss in lean mass 💪⬇️, however there was a GREATER loss in fat mass 🧈🔥.
Thus, there was an increase in lean mass as percent body composition 📊💪. This correlates with what we see clinically
There was an absolute loss in lean mass 💪⬇️, however there was a GREATER loss in fat mass 🧈🔥.
Thus, there was an increase in lean mass as percent body composition 📊💪. This correlates with what we see clinically
June 25, 2025 at 9:51 AM
What is the impact of tirzepatide on body composition? 🤔
There was an absolute loss in lean mass 💪⬇️, however there was a GREATER loss in fat mass 🧈🔥.
Thus, there was an increase in lean mass as percent body composition 📊💪. This correlates with what we see clinically
There was an absolute loss in lean mass 💪⬇️, however there was a GREATER loss in fat mass 🧈🔥.
Thus, there was an increase in lean mass as percent body composition 📊💪. This correlates with what we see clinically
Reposted by Michael Weintraub, MD
How should we think about the interesting bimagrumab & Semaglutide data #ADA2025 #weightloss #obesity How to assess meaningful functional benefit? www.statnews.com/2025/06/23/b...
Eli Lilly drug preserves lean mass in patients losing weight on Wegovy
Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.
www.statnews.com
June 23, 2025 at 6:58 PM
How should we think about the interesting bimagrumab & Semaglutide data #ADA2025 #weightloss #obesity How to assess meaningful functional benefit? www.statnews.com/2025/06/23/b...
Reposted by Michael Weintraub, MD
P2 data for the once monthly GIPR Antagonist GLP-1R agonist bispecific antibody, Maritide in people with #T2D as well as in #overweight and #obesity Even data for lower dose titration over several weeks in the same paper www.nejm.org/doi/full/10....
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial | NEJM
Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...
www.nejm.org
June 23, 2025 at 6:55 PM
P2 data for the once monthly GIPR Antagonist GLP-1R agonist bispecific antibody, Maritide in people with #T2D as well as in #overweight and #obesity Even data for lower dose titration over several weeks in the same paper www.nejm.org/doi/full/10....
We’ve gone from 2 to over a dozen trials of GLP1s in alcohol use disorders in only a few years.
This comes on the heels of numerous observational and pharmacoepidiologic data supporting a reduction in alcohol use in GLP1 users.
#ADA2025 #ADASciSessions
This comes on the heels of numerous observational and pharmacoepidiologic data supporting a reduction in alcohol use in GLP1 users.
#ADA2025 #ADASciSessions
June 22, 2025 at 7:46 PM
We’ve gone from 2 to over a dozen trials of GLP1s in alcohol use disorders in only a few years.
This comes on the heels of numerous observational and pharmacoepidiologic data supporting a reduction in alcohol use in GLP1 users.
#ADA2025 #ADASciSessions
This comes on the heels of numerous observational and pharmacoepidiologic data supporting a reduction in alcohol use in GLP1 users.
#ADA2025 #ADASciSessions
Continuous glucose monitors are an excellent tool… when they work!
Studies report up to 26% early failure rate of these devices.
#ADA2025 #ADASciSessions
Studies report up to 26% early failure rate of these devices.
#ADA2025 #ADASciSessions
June 22, 2025 at 4:52 PM
Continuous glucose monitors are an excellent tool… when they work!
Studies report up to 26% early failure rate of these devices.
#ADA2025 #ADASciSessions
Studies report up to 26% early failure rate of these devices.
#ADA2025 #ADASciSessions
There is a national shortage of endocrinologists!
The majority of the country do not have local access to endocrinologists.
80% of those with diabetes are cared for by a PCP and no endocrinologist.
#ADA2025 #ADASciSessions
The majority of the country do not have local access to endocrinologists.
80% of those with diabetes are cared for by a PCP and no endocrinologist.
#ADA2025 #ADASciSessions
June 22, 2025 at 3:06 PM
There is a national shortage of endocrinologists!
The majority of the country do not have local access to endocrinologists.
80% of those with diabetes are cared for by a PCP and no endocrinologist.
#ADA2025 #ADASciSessions
The majority of the country do not have local access to endocrinologists.
80% of those with diabetes are cared for by a PCP and no endocrinologist.
#ADA2025 #ADASciSessions
The prevalence of type 2 diabetes in the young is rising, and so are the complications.
80% of individuals develop a microvascular complication by 9 years over 9 years of follow-up!
#ADA2025 #ADASciSessions
80% of individuals develop a microvascular complication by 9 years over 9 years of follow-up!
#ADA2025 #ADASciSessions
June 22, 2025 at 3:04 PM
The prevalence of type 2 diabetes in the young is rising, and so are the complications.
80% of individuals develop a microvascular complication by 9 years over 9 years of follow-up!
#ADA2025 #ADASciSessions
80% of individuals develop a microvascular complication by 9 years over 9 years of follow-up!
#ADA2025 #ADASciSessions
❗ New CagriSema Phase 3 data released
Combination cagrilintide-semaglutide after 68 weeks in patients with Type 2 Diabetes and BMI > 27
⬇️ 13.7% weight loss vs 3.4% in placebo
⬇️ 1.8% a1c reduction vs 0.4% in placebo
73% had a1c <6.5%
🤢 72.5% had gastrointestinal side effects vs 34% in placebo
Combination cagrilintide-semaglutide after 68 weeks in patients with Type 2 Diabetes and BMI > 27
⬇️ 13.7% weight loss vs 3.4% in placebo
⬇️ 1.8% a1c reduction vs 0.4% in placebo
73% had a1c <6.5%
🤢 72.5% had gastrointestinal side effects vs 34% in placebo
June 22, 2025 at 2:26 PM
❗ New CagriSema Phase 3 data released
Combination cagrilintide-semaglutide after 68 weeks in patients with Type 2 Diabetes and BMI > 27
⬇️ 13.7% weight loss vs 3.4% in placebo
⬇️ 1.8% a1c reduction vs 0.4% in placebo
73% had a1c <6.5%
🤢 72.5% had gastrointestinal side effects vs 34% in placebo
Combination cagrilintide-semaglutide after 68 weeks in patients with Type 2 Diabetes and BMI > 27
⬇️ 13.7% weight loss vs 3.4% in placebo
⬇️ 1.8% a1c reduction vs 0.4% in placebo
73% had a1c <6.5%
🤢 72.5% had gastrointestinal side effects vs 34% in placebo
Tirzepatide in a target emulation trial demonstrates significantly lower MACE (HR 0.8) and all cause mortality (HR 0.6) compared to dulaglutide in T2DM. 🤯
#ADASciSessions #ADA2025
#ADASciSessions #ADA2025
June 22, 2025 at 9:51 AM
Tirzepatide in a target emulation trial demonstrates significantly lower MACE (HR 0.8) and all cause mortality (HR 0.6) compared to dulaglutide in T2DM. 🤯
#ADASciSessions #ADA2025
#ADASciSessions #ADA2025